ASCO-GU – Padcev and Keytruda impress again
The combo gets another slam dunk, this time in perioperative chemo-eligible MIBC.
Another solstice for CTLA-4
Solstice Oncology acquires porustobart from Harbour Biomed.
Pivotal Claudin18.2 candidates keep coming
New pivotal trials will soon start for LaNova’s ADC and FutureGen’s MAb.
Ellipses Pharma widens its orbit
The biotech licenses a China-developed anti-B7-H3 ADC.
ASCO-GI – Astellas makes a case for its Vyloy triplet
Data from the Ilustro trial support the initiation of the phase 3 Lucerna study.
NACLC 2025 – BioNTech gets a gotistobart boost
The first stage of Preserve-003 shows a survival benefit in post-PD-(L)1 lung cancer – with caveats.
BioNTech’s big gotistobart day approaches
Readout of the Preserve-003 trial in post-PD-(L)1 NSCLC is due in December.
